NCT03171623View on ClinicalTrials.gov

The Assessment of Single-Dose Safety,Tolerability, Pharmacokinetics and Pharmacodynamic of Globalagliatin Hydrochloride

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

April 5, 2017

Primary Completion Date

September 25, 2017

Study Completion Date

January 9, 2018

Conditions
Hyperglycaemia (Diabetic)Healthy Volunteers
Interventions
DRUG

globalagliatin hydrochloride

orally administration, single dose

DRUG

placebo

orally administration, single dose

Trial Locations (1)

Unknown

The First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors
lead

Yabao Pharmaceutical Group

INDUSTRY

NCT03171623 - The Assessment of Single-Dose Safety,Tolerability, Pharmacokinetics and Pharmacodynamic of Globalagliatin Hydrochloride | Biotech Hunter | Biotech Hunter